Exclusive License Agreement by and Between Takeda Pharmaceutical Company Limited and Neurocrine Biosciences, Inc. June 12, 2020Exclusive License Agreement • August 3rd, 2020 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances) • New York
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”), entered into as of June 12, 2020 (the “Execution Date”), is entered into by and between Takeda Pharmaceutical Company Limited, a Japanese corporation (“Takeda”), and Neurocrine Biosciences, Inc., a corporation organized and existing under the Laws of Delaware (“Neurocrine”). Takeda and Neurocrine are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
